KalVista Pharmaceuticals, Inc. — Operating Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8564566b-0f1c-4159-b2cc-54d1f9b93b2e/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-188.0M | 2024-05-01 – 2025-04-30 | evidence 0000950170-25-095011 |
| FY 2023 | $-140.4M | 2023-05-01 – 2024-04-30 | evidence 0000950170-24-082965 |
| FY 2022 | $-110.9M | 2022-05-01 – 2023-04-30 | evidence 0000950170-23-032298 |
| FY 2021 | $-96.6M | 2021-05-01 – 2022-04-30 | evidence 0000950170-22-012521 |
| FY 2020 | $-57.9M | 2020-05-01 – 2021-04-30 | evidence 0001564590-21-036441 |
| FY 2019 | $-40.5M | 2019-05-01 – 2020-04-30 | evidence 0001564590-20-031501 |
| FY 2018 | $-29.8M | 2018-05-01 – 2019-04-30 | evidence 0001564590-19-025009 |
| FY 2017 | $-18.7M | 2017-05-01 – 2018-04-30 | evidence 0001564590-18-017915 |
| FY 2016 | $-22.3M | 2016-05-01 – 2017-04-30 | evidence 0001564590-17-014286 |
| FY 2015 | $-15.2M | 2015-05-01 – 2016-04-30 | evidence 0001564590-17-014286 |
| FY 2014 | $-8.1M | 2014-05-01 – 2015-04-30 | evidence 0001564590-17-014286 |
| FY 2013 | $-5.2M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-015646 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
KalVista Pharmaceuticals, Inc. — all facts · Revenue · Net Income